89bio to net $275M from stock offering; Assembly Bio to pause work on one HBV inhibitor program
San Francisco-based biotech 89bio announced on Friday that it expects to rake in $275 million on a stock offering. The raise …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
